Compare Medtronic PLC (MDT) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Ferrari NV — how do they compare? Medtronic PLC trades at $82.89 (market cap $106.61B), while Ferrari NV trades at $370.3 (market cap $65.48B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | RACE | |
|---|---|---|
Market Cap | $106.61B | $65.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $517.65 |
52-Week Low | $73.75 | $314.63 |
Enterprise Value | $125.36B | $66.69B |
Dividend Yield | 3.46% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Ferrari (RACE) trades at $371.52, down 1.41% on the day, with a bullish technical signal from moving averages. The company exhibits strong fundamentals, including a 22.19% net income margin and consistent earnings beats, with Q2 2026 results due July 30, 2026. Recent news highlights institutional buying, a share buyback program, and the debut of its first electric vehicle, though the Luce model received mixed initial reception.
The outlook remains positive given analyst consensus, with a $467.50 price target implying significant upside. Key risks include execution on the EV transition and high valuation multiples. The stock presents a growth opportunity driven by brand strength and pricing power, but investors should weigh near-term volatility around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
